Latest news with #Medtronic
Yahoo
7 hours ago
- Business
- Yahoo
Does This Move Make Medtronic Stock a Buy?
Medtronic's diabetes care unit has grown faster than the rest of its business in recent years. However, the company decided to spin off this segment into a stand-alone corporation. Still, Medtronic has several growth avenues and an impeccable dividend program. 10 stocks we like better than Medtronic › Over the past few years, Medtronic (NYSE: MDT) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its fastest-growing segments. However, the healthcare leader recently announced some news regarding this unit that might surprise some investors. Let's find out more about it and discuss what it means for Medtronic's prospects. Medtronic markets several products within its diabetes care segment. Perhaps its most important line is its insulin pump franchise. One of the latest iterations of this was the MiniMed 780G, which came with several nifty features, including automatic insulin dose corrections. Medtronic also markets continuous glucose monitoring (CGM) systems that allow diabetes patients to keep track of their blood sugar levels, with constant measurements every few minutes. Additionally, it offers insulin pens and a software that collects information from CGM devices, insulin pumps, and smart pens to create reports to inform patients' progress or share with medical professionals. There is considerable room for growth in the diabetes market. Of the half-billion adults worldwide with diabetes, only 1% had access to CGM technology as of the end of 2023. One might think Medtronic would seize the vast untapped opportunity, especially considering its diabetes care unit's faster growth. During the company's fiscal 2025, ended April 25, Medtronic reported revenue of $33.6 billion, up 3.6% compared to the previous fiscal year. The company's diabetes care segment generated $2.8 billion in sales, with year-over-year growth of 10.7%. True, it still makes up a small part of its business, but given the massive worldwide opportunity, it might have eventually become its biggest growth driver if it kept up its much faster growth pace for a long time. However, Medtronic announced that it would spin off its diabetes care unit, which will become a stand-alone, publicly traded corporation within the next 18 months. Medtronic wants to simplify its portfolio and focus its resources on core, high-margin growth opportunities. That's the rationale management gave for the separation. What does it mean for investors? Medtronic would likely struggle to catch up with the leaders in the diabetes care field. Abbott Laboratories and DexCom dominate the CGM market. In the insulin pump niche, Medtronic has had to compete with companies such as Tandem Diabetes Care. Perhaps Medtronic felt it would not be competitive in these and other niches of the diabetes market over the long run, hence its decision to focus on markets where it "has leading core competencies," to borrow the company's phrasing. While Medtronic will lose its fastest-growing segment, its business should remain robust. The company still markets dozens of products across several other areas that generate consistent revenue and profits. In today's challenging environment, investors tend to gravitate toward steady and stable corporations like Medtronic. Furthermore, the healthcare leader recently announced important news. The company is requesting U.S. clearance for its Hugo robotic-assisted surgery (RAS) system in urologic procedures after the device delivered strong clinical trial results. Approval of Medtronic's RAS Hugo system in the U.S. should unlock massive opportunities, given the industry's underpenetration and significant runway for growth. Finally, Medtronic remains an excellent dividend stock, and it recently announced yet another payout hike. The medical device specialist has increased its dividends for 48 consecutive years -- just two more and it will join the exclusive rank of Dividend Kings. Even with the potential impact of tariffs, Medtronic has performed relatively well this year compared to broader equity markets. In the long run, it should be able to mitigate the effects of tariffs, given its diversified business and consistent earnings, which can enable it to shift its manufacturing around. Medtronic remains a top pick for long-term, income-oriented investors despite spinning off its fastest-growing unit. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic, long January 2027 $65 calls on DexCom, short January 2026 $85 calls on Medtronic, and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. Does This Move Make Medtronic Stock a Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Continuous Glucose Monitoring Devices Market Size expected to reach US$ 32.97 billion by 2031, Increasing Demand for Effective Diabetes Management Propels Growth
The Continuous Glucose Monitoring (CGM) devices market, valued at $12.63 billion in 2024 and projected to reach $32.97 billion by 2031, is growing at a 12.6% CAGR, driven by rising diabetes prevalence, home-based care, and technological advancements, with key players including Dexcom, Abbott, Medtronic, and Senseonics leading innovation in real-time, wearable, and non-invasive monitoring solutions. US & Canada, May 30, 2025 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the global continuous glucose monitoring devices market is observing significant growth owing to the increasing demand for effective diabetes management and the growing use of OTC products. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the continuous glucose monitoring devices market comprises a vast array of products and services that are expected to register strength in the coming years. To explore the valuable insights in the Continuous Glucose Monitoring Device Market report, you can easily download a sample PDF of the report - Overview of Report Findings Market Growth: The continuous glucose monitoring devices market is expected to reach US$ 32.97 billion by 2031 from US$ 12.63 billion in 2024, at a CAGR of 12.6% during the forecast period. Continuous glucose monitoring devices (CGMD) represent the most advanced technology for managing diabetes manually, featuring components such as sensors, transmitters, and monitors. These devices offer real-time updates on blood sugar levels. This information allows individuals to adjust their dietary choices or insulin doses as recommended by their healthcare provider. By providing real-time data, these devices help reduce the risk of hypoglycemia and hyperglycemia in those living with diabetes. Increasing Need for Effective Diabetes Management: Diabetes, especially type 2, is a growing global concern, with countries such as India seeing a significant increase. As per the International Diabetes Federation (IDF) Diabetes Atlas, ~10.5% of adults globally aged 20–79 years had diabetes in 2021. This number is projected to rise to 12.2% by 2045. According to the World Health Organization (WHO), ~77 million people aged 18 and older in India were living with diabetes, while ~25 million were considered pre-diabetic in 2022. This increasing incidence underscores the urgent need for proactive products and tools for advanced, user-friendly monitoring, such as CGM devices, to address the issue. CGM systems offer real-time insights into glucose levels, allowing users to make quick decisions about diet, exercise, and medication. This ongoing data helps achieve better blood sugar control, lower HbA1c levels, and prevent hypoglycemia, organ damage, etc. By detecting glucose fluctuations early—often before symptoms arise—CGM empowers patients and healthcare providers to intervene effectively. Surging Use of OTC Products: The availability of over-the-counter (OTC) CGM devices has greatly increased market growth by making glucose monitoring more accessible and affordable. Since these devices don't require prescriptions, individuals can easily purchase them from pharmacies, online retailers, or supermarkets. This convenience has led to widespread use among people with diabetes, those at risk, and health-conscious individuals looking to monitor their well-being. In March 2024, the US Food and Drug Administration (FDA) accepted the first OTC continuous glucose monitor (CGM) for marketing. The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) designed for individuals aged 18 and older who do not use insulin. This includes people with diabetes managing their condition with oral medications, as well as those without diabetes who want to understand the effect of diet and exercise on blood sugar levels. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. For Detailed Continuous Glucose Monitoring Device Market Insights, Visit: Market Segmentation Based on product, the continuous glucose monitoring devices market is segmented into sensors, transmitters, and receivers. The sensors segment held the largest share of the continuous glucose monitoring devices market in 2024. Based on testing sites, the continuous glucose monitoring devices market is bifurcated into fingertip testing and alternate site testing. The fingertip testing segment held a larger share of the continuous glucose monitoring devices market in 2024. In terms of application, the continuous glucose monitoring devices market is bifurcated into type-1 diabetes and type-2 diabetes. The type-2 diabetes segment held a larger share of the continuous glucose monitoring devices market in 2024. In terms of end user, the continuous glucose monitoring devices market is bifurcated into hospitals and clinics and self/home care. The hospitals and clinics segment held a larger share of the continuous glucose monitoring devices market in 2024. The continuous glucose monitoring devices market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: A few major companies operating in the continuous glucose monitoring devices market include B. Braun SE, F. Hoffmann-La-Roche Ltd, LifeScan Inc, Medtronic, Abbott Laboratories, Ypsomed Holding AG, Sensionics, Nipro Corp, GE Healthcare, and Novo Nordisk A/S. Trending Topics: Advanced Continuous Glucose Monitoring Devices, AI in Continuous Glucose Monitoring Devices, Type-2 Diabetes Management, and OTC Devices for Continuous Glucose Management, among others. Stay Updated on The Latest Continuous Glucose Monitoring Device Market Trends: Global Headlines on Continuous Glucose Monitoring Devices Philips-Medisize announced a partnership with GlucoModic to commercialize a proprietary non-invasive and wearable device. This partnership aims to develop a solution that is needle-free, accurate, and more affordable for diabetic patient to monitor their blood glucose levels. Medtronic received CE Mark approval for the "MiniMed 780G system" with the Simplera Sync, a disposable all-in-one Continuous Glucose Monitoring device that requires no finger pricks or overtaping. This new product will be available in Europe, with a phased commercial launch planned for Spring 2024. Dexcom launched a new Continuous Glucose Monitoring device, the "Dexcom G7." This device is the smallest and most accurate Continuous Glucose Monitoring option connected to the t:slim X2 insulin pump. The Dexcom G7 has the fastest sensor warm-up time at just 30 minutes and, along with the Dexcom G6, is the only Continuous Glucose Monitoring system capable of providing alerts without the need for finger pricks. Roche received the CE Mark for its AI-enabled continuous glucose monitoring solution, the Accu-Chek SmartGuide CGM. This device offers accurate real-time glucose readings for 14 days, helping adults with type 1 and type 2 diabetes with flexible insulin therapy. Purchase Premium Copy of Global Continuous Glucose Monitoring Device Market Size and Growth Report (2020-2031) at: Conclusion The growing prevalence of diabetes and rising use of OTC products for self-management drive the continuous glucose monitoring devices market growth. The utilization of Continuous Glucose Monitoring (CGM) systems has broadened its scope beyond insulin-dependent individuals to encompass those with type 2 diabetes, as well as health-conscious non-diabetics. This expansion is attributed to technological advancements such as smartphone integration, artificial intelligence, and non-invasive sensor technology. Adoption barriers are being removed by increased insurance coverage, OTC access, and other regulatory reforms, especially in large countries, including the US and Europe. Due to increased accessibility, cost, and user empowerment, the shift to OTC availability has democratized glucose monitoring, greatly expanding the industry and fostering long-term market growth. Talk to Us Directly: Related Reports: About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Home - in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Medtronic plc (MDT): A Bull Case Theory
We came across a bullish thesis on Medtronic plc (MDT) on Investing Intel's Substack. In this article, we will summarize the bulls' thesis on MDT. Medtronic plc (MDT)'s share was trading at $80.68 as of 23rd May. MDT's trailing and forward P/E were 22.35 and 14.08 respectively according to Yahoo Finance. An assembly line of medical devices being packed for distribution. Medtronic PLC (MDT) delivered robust Q4 and FY2025 results, showcasing solid execution across its portfolio and setting the stage for a strategic transformation. Quarterly revenue grew organically by over 5% to $8.93 billion, with adjusted EPS up 11% to $1.62, and operating profit rising 7.6% year over year to $2.5 billion—or nearly 13% on a constant currency basis. For the full fiscal year, Medtronic generated $33.54 billion in revenue, up nearly 5% organically, and delivered $5.49 in adjusted EPS. Strength was broad-based across all segments, with cardiovascular and diabetes leading the charge—each posting 12% organic growth, underscoring renewed momentum in key franchises. In a major strategic move, Medtronic announced plans to spin off its diabetes business within the next 18 months, aiming to streamline operations, improve focus, and enhance margin profile. The spin-off will be internally led, suggesting continuity and deep institutional knowledge to support the transition. This separation reflects management's intent to unlock value and pursue more focused innovation, particularly in core segments like cardiovascular, neurovascular, and surgical robotics. The diabetes unit, despite recent growth, has historically lagged in profitability and innovation compared to Medtronic's higher-margin units, and its spin-off could help drive a re-rating of MDT shares. Investors now see a cleaner, more focused medical device company emerging, backed by stable cash flow, improving margins, and strong earnings momentum. If successfully executed, the spin-off may unlock hidden value, positioning MDT as a leaner and more agile player in medtech. Previously, we have covered Medtronic plc (MDT) in April 2025 wherein we summarized a bullish thesis by Magnus Ofstad on Substack. The author emphasized the company's ongoing transformation amid operational challenges and strategic realignment. The article highlighted activist investor Starboard Value's involvement as a potential catalyst for streamlining operations, pushing divestitures, and revitalizing innovation, particularly through platforms like the HUGO Robotic Surgery System. Despite trailing peers in growth and margins, MDT was framed as a defensive value play with upside potential if it successfully executes on its strategic pivot. Since our last coverage, the stock has traded mostly flat as of 27th March. Medtronic plc (MDT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 63 hedge fund portfolios held MDT at the end of the first quarter which was 67 in the previous quarter. While we acknowledge the risk and potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MDT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities
Growth is driven by the aging population, rising chronic diseases, and self-administration practices. Advances in technology, new product launches, and favorable policies bolster growth. Injectable drug delivery devices, particularly autoinjectors, lead the market, thanks to user-centric designs improving patient adherence. North America holds the largest share, fueled by a notable chronic disease presence, while the Asia Pacific is poised for the fastest growth. Major players include Abbott, Medtronic, and Novartis. Explore insights on market trends, key drivers, and growth strategies in the comprehensive market report. Drug Device Combination Products Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Drug Device Combination Products Market by Type (Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application (Diabetes, Oncology, Pain, Opthamology), End User (Hospital, Home Care), and Region - Global Forecast to 2030" report has been added to global drug device combination products market is projected to reach USD 379.17 billion by 2030 from USD 243.02 billion in 2025, at a CAGR of 9.3% during the forecast period. The rapid expansion of the geriatric demographic, coupled with a notable increase in patients suffering from chronic conditions such as diabetes and cardiovascular diseases, is projected to drive the market for drug-device combination products significantly. Additionally, the steady rise in self-administration practices and a heightened emphasis on patient-centric design and adherence to treatment regimens are expected to further propel market growth. Technological advancements in drug-device combination products, the introduction of innovative products, and favorable reimbursement frameworks, along with supportive government policies, are all anticipated to enhance market dynamics. Furthermore, strategic investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of these combination products will likely contribute significantly to market expansion. Currently, North America dominates this market due to its substantial burden of chronic diseases, particularly diabetes, which enlarges the patient demographic that relies on these combination products. The region's market growth is further bolstered by the presence of several major industry players and supportive reimbursement policies that facilitate access to innovative therapies. Meanwhile, the Asia Pacific region is projected to experience the highest CAGR during the forecast period, indicating a burgeoning demand and potential for expansion in this sector. The major players operating in the drug device combination products market are Abbott (US), Boston Scientific Corporation (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AbbVie Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Stryker (US), B. Braun SE (Germany), Terumo Corporation (Japan) and Kaleo, Inc.(US).The injectable drug delivery devices segment is expected to grow at the highest CAGR during the forecast the realm of drug-device combination products, injectable drug delivery systems command the largest market share and are experiencing accelerated growth. This trend is predominantly due to their capacity for rapid, targeted administration of complex biologics and other therapies that are unsuitable for oral delivery routes. The escalating prevalence of chronic diseases, such as diabetes and cancer, is a primary driver of demand in this sector. Additionally, the industry is witnessing a paradigm shift towards self-administration facilitated by user-centered designs, including autoinjectors and pen injectors. Continuous innovation in device technology is enhancing patient comfort, safety, and adherence, further propelling market autoinjectors subsegment of the injectable drug delivery devices segment captured the largest market share in injectable drug delivery devices can be subcategorized into prefilled syringes, pen injectors, autoinjectors, needle-free injectors, and wearable injectors. Among these, autoinjectors have experienced a pronounced growth trajectory in the market due to their user-friendly design, convenience, and capability to administer accurate doses of medication. These features make autoinjectors particularly suitable for patients with chronic conditions such as diabetes and multiple sclerosis. The architecture of autoinjectors facilitates self-administration, which enhances patient adherence to treatment regimens and minimizes the necessity for frequent visits to healthcare facilities. Given the rising emphasis on home-based care and patient-centric therapeutic solutions, the market for autoinjectors is poised for significant Attributes: Report Attribute Details No. of Pages 346 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $243.02 Billion Forecasted Market Value (USD) by 2030 $379.17 Billion Compound Annual Growth Rate 9.3% Regions Covered Global Market Dynamics Drivers Rising Prevalence of Chronic Diseases Growing Adoption of Biologics and Vaccines High R&D Investments from Government Organizations and Private Bodies Shift Toward Personalized Medicines and Patient-Centric Care Rising Popularity of Self-Administered Medicines Restraints Stringent Regulatory Policies and Compliance Hurdles Focus on Alternative Drug Delivery Methods Opportunities Increased Preference for Minimally Invasive Products High Growth Potential in Emerging Economies Growing Adoption of Drug Device Combination Products and Expanding Biologics Market Challenges Heavy Financial Impact of Drug Wastage and Device Malfunction Lack of Standardized Reimbursement Policies Limited Training and Education for Healthcare Professionals Lack of Medical Specialists and Surgeons Industry Trends Rising Popularity of Self-Administered Medicines and Home Care Settings Integration of Drug Device Combination Products with Smart Connected Devices Technology Analysis Key Technologies Wearable Technologies Drug-Eluting Technologies Complementary Technologies Connected Health and Digital Technologies Adjacent Technologies Advanced Materials and Biopolymers Case Study Analysis Minimed 780G Diabetes Management System to Combine Continuous Glucose Monitoring with Automated Insulin Delivery Digiinhaler-Smart Inhaler for Asthma/Copd to Track Lung Function Adoption of Pen Injectors by Nemera France to Improve Therapeutic Outcomes Business Impacts Supply Chain Analysis Trends/Disruptions Impacting Customers' Businesses Investment & Funding Scenario Reimbursement Scenario Analysis Clinical Pipeline Analysis Impact of AI/Gen AI on Drug Device Combination Products Market Impact of 2025 US Tariff on Drug Device Combination Products Market Companies Featured Key Players Abbott Eli Lilly and Company Medtronic Novo Nordisk A/S Novartis AG Sanofi Boston Scientific Corporation Becton, Dickinson and Company Merck KGaA AbbVie Inc. Teva Pharmaceutical Industries Ltd. Stryker B. Braun SE Terumo Corporation Other Players Tandem Diabetes Care, Inc. Cequr Simplicity Intarcia Therapeutics, Inc. Halozyme, Inc. Kaleo, Inc. Lead Chemical Co. Ltd. Purdue Pharma L.P. Alvogen Evolutis Mundipharma International Limited Sparsha Pharma International Pvt. Ltd. Supernus Pharmaceuticals, Inc. Alcon Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Drug Device Combination Products Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
24-05-2025
- Business
- Yahoo
Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
The board of Medtronic plc (NYSE:MDT) has announced that it will be increasing its dividend by 1.4% on the 11th of July to $0.71, up from last year's comparable payment of $0.70. This will take the dividend yield to an attractive 3.5%, providing a nice boost to shareholder returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. Before this announcement, Medtronic was paying out 77% of earnings, but a comparatively small 69% of free cash flows. Since the dividend is just paying out cash to shareholders, we care more about the cash payout ratio from which we can see plenty is being left over for reinvestment in the business. Looking forward, earnings per share is forecast to rise by 25.2% over the next year. If the dividend continues along recent trends, we estimate the payout ratio will be 67%, which would make us comfortable with the sustainability of the dividend, despite the levels currently being quite high. See our latest analysis for Medtronic The company has been paying a dividend for a long time, and it has been quite stable which gives us confidence in the future dividend potential. The dividend has gone from an annual total of $1.22 in 2015 to the most recent total annual payment of $2.80. This implies that the company grew its distributions at a yearly rate of about 8.7% over that duration. Dividends have grown at a reasonable rate over this period, and without any major cuts in the payment over time, we think this is an attractive combination as it provides a nice boost to shareholder returns. Investors who have held shares in the company for the past few years will be happy with the dividend income they have received. Unfortunately, Medtronic's earnings per share has been essentially flat over the past five years, which means the dividend may not be increased each year. Earnings are not growing quickly at all, and the company is paying out most of its profit as dividends. This isn't the end of the world, but for investors looking for strong dividend growth they may want to look elsewhere. Overall, this is probably not a great income stock, even though the dividend is being raised at the moment. The company has been bring in plenty of cash to cover the dividend, but we don't necessarily think that makes it a great dividend stock. Overall, we don't think this company has the makings of a good income stock. Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. However, there are other things to consider for investors when analysing stock performance. As an example, we've identified 1 warning sign for Medtronic that you should be aware of before investing. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
